Inspired by Arnold Palmer’s Iconic Golf Career, New Wellness Brand Arnie’s Tees Up Premium Topical Products

ORLANDO, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) — Arnie's, a bold new natural wellness brand inspired by Arnold Palmer's legacy of performance, embodies the unstoppable spirit that made him a global icon. Created in partnership with Arnold Palmer Enterprises and leading CBD Manufacturer Naternal, Arnie's debuts with a premium collection of topicals designed to help […]

What Taxpayers Should Know About Big Changes to Form 1099-K Reporting

(NYSE:HRB), KANSAS CITY, Mo., Jan. 22, 2025 (GLOBE NEWSWIRE) — The millions of Americans with revenue-generating side hustles and casual sellers may be in for a big surprise this January–an unexpected tax form called the 1099-K. Payment platforms, apps and online marketplaces must issue a Form 1099-K to anyone who received $5,000 or more in

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

(NASDAQ:ALXO), Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operations Dr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experience Dr. Takimoto brings a distinguished track record in oncology and drug development with

Matthews Sends Letter to Shareholders Outlining Reasons to Vote on the WHITE Proxy Card For All Three Matthews Director Nominees

(NASDAQ:MATW), PITTSBURGH, Jan. 22, 2025 (GLOBE NEWSWIRE) — Matthews International Corporation (NASDAQ GSM: MATW) (“Matthews” or the “Company”) today sent a letter to its shareholders emphasizing the Company's commitment to long-term value creation. Key highlights from the letter include: Your Board has taken decisive actions to enhance long-term shareholder value – particularly the strategic sale

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

(NASDAQ:LSTA), Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4 complete responses observed in the certepetide treatment group compared to none in placebo group Data from Cohort B expected in the coming months, with

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

(NASDAQ:PULM), SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE(TM) platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK

NFL Alumni Joel Dreessen and Le-Lo Lang Team Up With HeartFlow and Boone Heart Institute to Launch GAMEFILM Registry to Assess Heart Disease Risks in Retired Football Players

Registry will use HeartFlow FFRCT and Plaque Analysis to help inform strategies for prevention, earlier detection and improved care for former NFL athletes at high risk for coronary artery disease MOUNTAIN VIEW, Calif. and GREENWOOD VILLAGE, Colo., Jan. 22, 2025 (GLOBE NEWSWIRE) — HeartFlow, Inc., the global leader in non-invasive artificial intelligence (AI) heart care

Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

(NasdaqGM:AVDL), DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient

IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) — IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will leverage IMMvention's investigational small-molecule BACH1

Scroll to Top